PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group
about
sameAs
IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS)Identification of a direct Dlx homeodomain target in the developing mouse forebrain and retina by optimization of chromatin immunoprecipitationPAX3-FOXO1 fusion gene in rhabdomyosarcomaRhabdomyosarcoma: Advances in Molecular and Cellular BiologyA comparative review of canine and human rhabdomyosarcoma with emphasis on classification and pathogenesisRASSF tumor suppressor gene family: biological functions and regulationEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesAlveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature reviewInducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expressionGlobal gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomasVimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studiesIncidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingRecurrent fusion RNA DUS4L-BCAP29 in non-cancer human tissues and cells.Intergenically Spliced Chimeric RNAs in Cancer.Lineage of origin in rhabdomyosarcoma informs pharmacological responseChimeric RNAs generated by intergenic splicing in normal and cancer cells.Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiationAberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profilingThe role of nuclear morphometry in prediction of prognosis for rhabdomyosarcoma in children.NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors.Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.Molecular strategies for detecting chromosomal translocations in soft tissue tumors (review).NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcomaFANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.Pediatric oncology.Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.Neoplasms associated with germline and somatic NF1 gene mutationsFOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.Anaplastic rhabdomyosarcoma in TP53 germline mutation carriersNew therapeutic targets in soft tissue sarcoma.Rhabdomyosarcoma: current challenges and their implications for developing therapies.Notch signaling in pediatric soft tissue sarcomasMetastatic malignant ectomesenchymoma initially presenting as a pelvic mass: report of a case and review of literature.Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma.Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.
P2860
Q24319144-8240160E-E8AA-487F-AA8A-2DCD788547B8Q24633783-277DBEA6-6938-4342-A9EA-A2F51B19995AQ24646520-D572D2EF-E4CE-4B44-BB55-DD5AB033CA5DQ26784207-9FC0487A-0C73-4FF3-B85B-CEB8A66924CDQ26852801-AB097E29-2BE6-49C6-B7EF-DFBA758BFC20Q26866080-9C6B7BA6-EC26-4A70-9F47-996B2DA52524Q26999187-FEDB45B9-7CDD-4BF9-BEB9-3F598B094A75Q28067923-368D30F8-10FA-495B-B401-F2BF641F292CQ28265800-4834C293-2824-4B2A-96A1-77D39CC3E311Q28300128-4240077D-374D-4772-95CB-1BB2A2FCC2EEQ28473693-59ECF19B-D69C-4498-BB1F-E51C8FA618F7Q28741842-FCC17DB2-1F21-4724-919A-D5FAA1BF34BBQ30252613-27F780D0-3757-485A-897A-4CC63ACD9F53Q30274742-1286393D-662A-4727-8C04-A09031DF85C4Q30411722-6B489126-D3E5-46B7-8CDE-2A3115C34679Q30458901-D845EFBE-A7B6-499D-A2CA-2EEA0290A0F3Q30491274-9844DFF7-9842-4205-9E80-AA49415CC295Q30534479-43595D7F-C65B-4BBB-83C0-30C4AE524984Q30563970-F115C5D6-E169-43C6-BE98-7705AEE7D59CQ31119082-8E088DFD-B04A-4EC0-B126-7391BDBFDD97Q33424837-6E5ED585-EC6F-4E29-9C1F-D720BE637EEBQ33598764-8720756B-3371-436F-A16A-9B524697004EQ33615694-4581BED3-1F09-47D8-A93E-A100AF115D4CQ33688560-16A555D8-5E23-4677-9EB7-70F48D301866Q33747747-813BD20A-DD7C-4451-8250-4D8E00BF6736Q33779367-3A244670-622C-4E2C-AF6D-1076C0F5970EQ33916861-8B263F31-0B81-41B8-9215-D1B1D0F259DFQ34028460-6FB395BC-F293-4059-A427-BDDBC903C815Q34038452-6C750E89-9E76-4FF3-B592-6914EE9679BFQ34069048-44AEA7ED-E1D3-4041-A6E6-5F3B66B809B1Q34125947-8EBC283E-A385-4277-81E4-ED0868C1DD13Q34191937-07D5CDE4-BDD4-4DC1-A6DE-39160CA31935Q34235576-BD1AA279-EE8F-4CFD-B608-B144476677BEQ34267924-00667E0C-CEB5-4EA7-9F8B-A4F37675F759Q34400242-04AFE76B-F219-48FC-803A-8E5BF85D360EQ34480012-0BA68ADC-49D4-4237-9648-338C1270FB85Q34487696-6D774E4C-3AA6-4EF7-9FC7-975C081C1C1BQ34508636-5805641D-B548-4C1B-BF7B-36432D3B96A7Q34547814-F7B6B866-626F-46CF-8445-B613FCBE0A50Q34578460-1E98E6A7-0F4F-4FA9-97B3-7DF657CCF224
P2860
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@ast
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@en
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@nl
type
label
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@ast
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@en
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@nl
prefLabel
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@ast
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@en
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@nl
P2093
P3181
P356
P1476
PAX3-FKHR and PAX7-FKHR gene f ...... the children's oncology group
@en
P2093
Frederic G Barr
Harold M Maurer
James C Lynch
Jerian F Lim
Julia A Bridge
Poul H B Sorensen
Stephen J Qualman
Timothy J Triche
William M Crist
P304
P3181
P356
10.1200/JCO.2002.03.137
P407
P577
2002-06-01T00:00:00Z